Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling
High protection during peak ages of sexual activity in high-income countries would likely mitigate any potential rebounds in HPV infection and cervical cancer under the most pessimistic assumptions of 1-dose efficacy and duration.
Authors
- Emily Annika Burger (ORCID: https://orcid.org/0000-0002-6657-5849)
- Jean‐François Laprise (ORCID: https://orcid.org/0009-0009-7938-1400)
- Élodie Bénard (ORCID: https://orcid.org/0000-0002-7503-0664)
- Marc Brisson (ORCID: https://orcid.org/0000-0003-3912-6447)
- Mark Jit (ORCID: https://orcid.org/0000-0001-6658-8255)
- Mélanie Drolet
- Lauri E. Markowitz (ORCID: https://orcid.org/0000-0002-2480-9520)
- Stephen Sy
- Chantal Sauvageau (ORCID: https://orcid.org/0000-0002-4300-1658)
- Éléonore Chamberland
- Jane J. Kim (ORCID: https://orcid.org/0000-0002-9892-9170)
Institutions
- Centers for Disease Control and Prevention (US)
- University of Oslo (NO)
- National Center for Immunization and Respiratory Diseases (US)
- London School of Hygiene & Tropical Medicine (GB)
- Institut National de Santé Publique du Québec (CA)
- Centre hospitalier de l'Université Laval (CA)
- Université Laval (CA)
- University of Hong Kong (HK)
Publication Details
- Journal
- JNCI Monographs
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/jncimonographs/lgae038
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Bill and Melinda Gates Foundation
- Western Canada Research Grid
- Alliance de recherche numérique du Canada
- Centers for Disease Control and Prevention